Esperion ( (ESPR) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Esperion Therapeutics, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The primary reason for the delay is the company’s need for additional time to complete its financial closing procedures, following the identification and correction of errors in its earnings release. Esperion expects to file the report no later than five calendar days after the prescribed due date. The company has not indicated any significant changes in financial results from the previous year. Ongoing compliance efforts are being managed by CEO Sheldon L. Koenig, who has signed the notification.
The most recent analyst rating on (ESPR) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.
Spark’s Take on ESPR Stock
According to Spark, TipRanks’ AI Analyst, ESPR is a Neutral.
Esperion’s overall stock score is driven by strong technical momentum and positive earnings call sentiment, indicating potential growth. However, significant financial challenges, including negative equity and ongoing losses, weigh heavily on the score. The company’s strategic initiatives and corporate events provide some optimism for future improvement.
To see Spark’s full report on ESPR stock, click here.
More about Esperion
Average Trading Volume: 4,788,524
Technical Sentiment Signal: Sell
Current Market Cap: $370.6M
See more data about ESPR stock on TipRanks’ Stock Analysis page.